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A system of novel nanoparticles of star-shaped cholic acid-core polylactide-D-α-tocopheryl polyethylene glycol
1000 succinate (CA-PLA-TPGS) block copolymer was developed for paclitaxel delivery for breast cancer
treatment, which demonstrated superior in vitro and in vivo performance in comparison with paclitaxel-loaded
poly(D,L-lactide-co-glycolide) (PLGA) nanoparticles and linear PLA-TPGS nanoparticles. The paclitaxel- or
couramin 6-loaded nanoparticles were fabricated by a modified nanoprecipitation method and then
characterized in terms of size, surface charge, surface morphology, drug encapsulation efficiency, and in vitro
drug release. The CA-PLA-TPGS nanoparticles were found to be spherical in shape with an average size of
around 120 nm. The nanoparticles were found to be stable, showing no change in the particle size and
surface charge during 90-day storage of the aqueous solution. The release profiles of the paclitaxel-loaded
nanoparticles exhibited typically biphasic release patterns. The results also showed that the CA-PLA-TPGS
nanoparticles have higher antitumor efficacy than the PLA-TPGS nanoparticles and PLGA nanoparticles in vitro
and in vivo. In conclusion, such nanoparticles of star-shaped cholic acid-core PLA-TPGS block copolymer could
be considered as a potentially promising and effective strategy for breast cancer treatment.
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Cancer remains a major public health problem worldwide
[1]. The three most commonly diagnosed types of cancer
among women in 2012 were that of the breast, lung and
bronchus, and colorectum, accounting for about half of the
estimated cancer cases in women [1]. However, current
treatment options for breast cancer are still limited mainly
to surgical resection, chemotherapy, and radiotherapy,
which are highly aggressive and/or nonspecific and often
accompanied with undesirable and potentially serious side
effects because anticancer drugs also exert excessive
toxicity to healthy tissues and cells [2,3]. Nanomedicine,
especially drug formulation by polymeric nanoparticles,
has shown a great deal of promise to provide solutions to* Correspondence: zhengy@sz.tsinghua.edu.cn; alice_sunll@163.com
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in any medium, provided the original work is psuch problems in cancer treatment [4,5]. In recent years, a
lot of attention has been paid to the biodegradable
polymeric nanoparticles for their passive and active
drug targeting to the desired sites after various routes
of administration [6,7]. In addition, the nanoparticles
used as drug carriers possess other advantages including
a stable structure, high entrapment efficiency, high cellular
uptake, more desirable biodistribution, and more reason-
able pharmacokinetics as well as preferentially accumulate
at the tumor site through the enhanced permeability and re-
tention effect [8,9]. Polymeric nanoparticles were also found
to reduce or overcome drug resistance of tumor cells [10].
Biodegradable polymers have great application potential
in biomedical fields including drug delivery and tissue
engineering. Among them, the polyester family including
poly(D,L-lactide-co-glycolide) (PLGA), polylactide (PLA),
and polyglycolide (PGA) is most extensively investigated
due to its good biocompatibility and biodegradability
[9,11]. Despite the well-established importance, this kind
of polymers still has limitations in particular applications.Open Access article distributed under the terms of the Creative Commons
g/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction
roperly cited.
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degradation products of these polyesters cause unfavorable
effects. In addition, the degradation rate of polyesters such
as PLA and PLGA is too slow due to their hydrophobic
nature to meet the therapeutic needs [12,13]. It was also
reported that PLA- and PLGA-based nanoparticles can be
rapidly cleared in the liver and captured by the reticuloen-
dothelial system (RES) when they are administrated into
the blood circulation [14,15]. These drawbacks could be
overcome by the introduction of D-α-tocopheryl polyethyl-
ene glycol 1000 succinate (TPGS) into the hydrophobic
PLA backbone [16]. TPGS, a water-soluble derivative of
the natural form of D-α-tocopherol, is formed by esterifica-
tion of vitamin E succinate with poly(ethylene glycol)
(PEG) 1000. It was found that TPGS could improve the
aqueous solubility of drugs including taxanes, antibiotics,
cyclosporines, and steroids. In addition, TPGS could serve
as an excellent molecular biomaterial for overcoming
multidrug resistance and as an inhibitor of P-glycoprotein
to increase the cytotoxicity and oral bioavailability of
antitumor agents [17].
Though PLGA-based nanoparticles and PLA-TPGS-based
nanoparticles have been extensively studied as delivery
vehicles of drugs, most of them were focused on
making use of linear polymers. In recent years, branched
polymers, such as hyper-branched polymers, star-shaped
polymers, and dendrimers, have obtained great attention
due to their useful mechanical and rheological properties
[9,18,19]. A star-shaped block polymer is a branched
polymer molecule in which a single branch point
(core) gives rise to multiple linear chains or arms
[20]. In comparison with linear polymers at the same
molar mass, nanocarriers based on a star-shaped polymer
molecular structure showed a smaller hydrodynamic
radius, lower solution viscosity, higher drug content, and
higher drug entrapment efficiency [21,22]. Therefore, in
this research, novel delivery systems of star-shaped
block copolymers based on PLA and TPGS with
unique architectures were developed, which would
provide valuable insights for fabricating ideal and use-
ful drug carriers for nanomedicine applications
[23,24]. Cholic acid (CA) is one of the two major bile
acids produced by the liver where it is synthesized
from cholesterol. It is composed of a steroid unit
with one carboxyl group and three hydroxyl groups.
CA was chosen as the polyhydroxy initiator due to its
biological origin, which may obtain better biocompati-
bility for polymers incorporated with the CA moiety
[25]. Moreover, it was reported that CA-functionalized star-
shaped polymers could exhibit faster hydrolytic degradation
rates in comparison with linear homopolymers such as
PLA and poly(ε-caprolactone) (PCL). The existence of the
CA moiety in biomaterials could also significantly increase
both cell adherence and proliferation [26].In this research, the star-shaped block copolymer
CA-PLA-TPGS with three branch arms was used for
developing a superior nanocarrier of anticancer agents
with satisfactory drug content and entrapment efficiency for
breast cancer treatment. The star-shaped CA-PLA-TPGS
nanoparticles containing paclitaxel (PTX) as a model
drug were characterized, and the anticancer effect of
nanoparticles was evaluated both in vitro and in vivo.
Methods
Materials
TPGS, 4′-6′-diamino-2-phenylindole (DAPI), and PLA
(Mw approximately 25,000) were purchased from
Sigma-Aldrich (St. Louis, MO, USA). CA-PLA-TPGS
copolymer (Mw approximately 23,000) and PLA-TPGS
(Mw approximately 23,000) copolymer were obtained
from the Graduate School at Shenzhen, Tsinghua University.
PTX was provided by Beijing Union Pharmaceutical Factory
(Beijing, China). All chromatographic solvents were of
high-performance liquid chromatography (HPLC)-grade
quality, and all other chemicals used were of the highest
grade commercially available. Human breast adenocarcin-
oma cell line MCF-7 was obtained from American Type
Culture Collection (ATCC; Rockville, MD, USA).
Characterization of CA-PLA-TPGS copolymers
Proton nuclear magnetic resonance (1H NMR; Bruker
AMX 500, Madison, WI, USA) was applied to confirm
the structure of the synthesized CA-PLA-TPGS copoly-
mer. Fourier transform infrared (FTIR) spectrophotom-
etry (Thermo Nicolet, Madison, WI, USA) was further
applied to investigate the molecular structure of the
CA-PLA-TPGS copolymer. In brief, the samples for
FTIR analysis were prepared by grinding 99% KBr
with 1% CA-PLA-TPGS copolymer and then pressing
the mixture into a transparent tablet.
Fabrication of PTX-loaded nanoparticles
A modified nanoprecipitation method was used to
entrap PTX into the CA-PLA-TPGS nanoparticles (NPs)
[9]. Briefly, a pre-weighed amount of drug powder and
100 mg of CA-PLA-TPGS copolymer were dissolved in
8 mL of acetone by vortexing and sonication. This mixture
was dropwise added into 100 mL of 0.03% TPGS aqueous
solution under stirring. The resulting nanoparticle suspen-
sion was then stirred at room temperature overnight to
remove acetone completely. The nanoparticle suspension
was centrifuged at 25,000 rpm for 15 min and then
washed two to three times to remove the emulsifier and
unloaded drug. In the end, the dispersion was lyophilized
for 48 h for further use. PTX-loaded PLGA nanoparticles
and PLA-TPGS nanoparticles and coumarin 6-loaded
CA-PLA-TPGS NPs were fabricated in a similar manner.
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phate buffer solution (PBS) before use.
Characterization of PTX-loaded nanoparticles
Size, surface charge, and morphology of the nanoparticles
The nanoparticle size and zeta potential were deter-
mined using Malvern Mastersizer 2000 (Zetasizer Nano
ZS90, Malvern Instruments Ltd., Malvern, UK). Before
measurement, the freshly fabricated nanoparticles were
appropriately diluted. All measurements were measured
at room temperature after equilibration for 10 min. The
data were obtained with the average of three measurements.
The surface morphology of nanoparticles was exam-
ined by field emission scanning electron microscopy
(FESEM, JEOL JSM-6301F, Tokyo, Japan). To prepare
samples for FESEM, the nanoparticles were fixed on the
stub using a double-sided sticky tape and then coated
with a platinum layer using a JFC-1300 automatic fine
platinum coater (JEOL, Tokyo, Japan) for 40 s.
Drug content and entrapment efficiency
To determine the contents of drug loading (LC) and en-
trapment efficiency (EE) of the PTX-loaded nanoparticles,
a predetermined amount of nanoparticles was dissolved in
1 mL methylene dichloride under vigorous vortexing. The
solution was transferred to 5 mL of mobile phase
consisting of acetonitrile and deionized water (50:50, v/v).
A nitrogen stream was introduced to evaporate the
methylene dichloride for approximately 20 min, and then
a clear solution was obtained for HPLC analysis (LC 1200,
Agilent Technologies, Santa Clara, CA, USA). A reverse-
phase C18 column (250 × 4.6 mm, 5 μm, Agilent Tech-
nologies, Santa Clara, CA, USA) was used at 25°C. The
flow rate of the mobile phase was 1 mL/min. The column
effluent was detected using a UV detector at λmax of
227 nm. The measurement was performed in triplicate.
The LC and EE of the PTX-loaded nanoparticles were
calculated by the following equations, respectively:
LC %ð Þ ¼ Weight of PTX in the nanoparticles
Weight of the nanoparticles
 100%;
EE %ð Þ ¼ Weight of PTX in the nanoparticles
Weight of the feeding PTX
 100%:
In vitro drug release assay
In vitro PTX release from nanoparticle formulations was
performed as described previously. In brief, 5 mg of
accurately weighted lyophilized nanoparticles was put
into a centrifuge tube and redispersed in 8 mL PBS
(containing 0.1% w/v Tween 80, pH 7.4). The tube was
put into an orbital shaker water bath and vibrated at 130rpm at 37°C. At certain time intervals, the tube was
taken out and centrifuged at 25,000 rpm for 15 min. The
supernatant was then transferred into a glass test tube
for HPLC analysis. The pellet was resuspended in 8 mL
fresh PBS and put back into the shaker bath for subsequent
determination. The accumulative release of PTX from
nanoparticles was plotted against time.
Cellular uptake of nanoparticles
In this research, coumarin 6 served as a model fluorescent
molecule, which can be entrapped in the linear PLGA
nanoparticles, linear PLA-TPGS nanoparticles, and star-
shaped CA-PLA-TPGS nanoparticles for qualitative and
quantitative studies on cellular uptake by tumor cells such
as MCF-7 cells. MCF-7 cells were cultured in Dulbecco's
modified essential medium (DMEM) supplemented with
10% heat-inactivated fetal bovine serum and antibiotics.
The culture was kept in 95% air humidified atmosphere
containing 5% CO2 at 37°C. The cells were incubated
with 250 μg/mL coumarin 6-loaded CA-PLA-TPGS
nanoparticles at 37°C for 2 h, rinsed with cold PBS
three times, and then fixed by methanol for 25 min.
Cells were stained with DAPI for 30 min to display
the nuclei and rinsed twice with PBS.
The MCF-7 cells were observed by confocal laser
scanning microscopy (CLSM; LSM 410, Zeiss, Jena,
Germany) with an imaging software. The images of the
cells were determined with a differential interference
contrast channel, and the images of coumarin 6-loaded
nanoparticles and the nuclei of the cells stained by DAPI
were recorded with the following channels: a blue channel
(DAPI) with excitation at 340 nm and a green channel
(coumarin 6) with excitation at 485 nm [27,28].
For the quantitative studies, MCF-7 cells at the density
of 1 × 104 cells/well were plated in 96-well plates and
kept overnight. The cells were equilibrated with Hank's
buffered salt solution (HBSS) at 37°C for 60 min before
coumarin 6-loaded nanoparticles were added at concen-
trations of 100, 250, and 500 μg/mL. After incubation
for 2 h, the medium was removed and the wells were
rinsed three times with 50 μL cold PBS. Finally, 50 μL of
0.5% Triton X-100 in 0.2 N sodium hydroxide was put
into each sample well to lyse the cells.
In vitro cytotoxicity of PTX-loaded nanoparticles
MCF-7 cells were seeded in 96-well plates at the density
of 5 × 103 viable cells per well in 100 μl of culture medium
and incubated overnight. The cells were incubated
with the PTX-loaded CA-PLA-TPGS nanoparticles,
PLA-TPGS nanoparticle suspension, and Taxol® at
equivalent drug concentrations ranging from 0.25 to
25 μg/mL or the placebo CA-PLA-TPGS nanoparticles of
the same particle concentration for 24, 48, and 72 h. At
certain time intervals, the nanoparticles were replaced
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diphenyltetrazolium bromide (MTT; 5 mg/mL), and cells
were then incubated for additional 4 h. MTT was aspi-
rated off and DMSO was added to each well to solubilize
the formazan crystals formed in viable cells. Absorbance
was recorded at 570-nm wavelength using a 96-well
microplate reader. Untreated cells were considered as a
negative control with 100% viability, and cells without
addition of MTT were performed as blank to calibrate the
spectrophotometer to zero absorbance. The half maximal
inhibitory concentration (IC50), the drug concentration
at which cell growth was inhibited by 50% relative to
untreated control cells, was calculated by curve fitting
of the cell viability versus drug concentration data [29].
In vivo studies
The Administrative Committee on Animal Research in
the Anhui University of Science and Technology approved
all the protocols for the proposed human breast cancer
cell lines and animal experiments. Female severe com-
bined immunodeficient (SCID) mice weighing 15 to 20 g
were obtained from the Institute of Laboratory Animal
Sciences, Chinese Academy of Medical Science. MCF-7
cancer cells in the medium were inoculated subcutane-
ously to mice in the amount of 2 × 106 cells per mouse at
the right axilla, and the subcutaneous tumor growth in
each mouse was monitored. The length and width of
tumors were determined using a vernier caliper, and the
tumor volume (V) was calculated as V = d2 × D / 2, where
d and D are the shortest and the longest diameter of the
tumor in millimeters, respectively [30]. When the tumor
volume reached approximately 50 mm3 (set as the 0 day),
treatments were performed. The mice were randomly
divided into three groups (each group has five mice,
n = 5). The two formulations of paclitaxel, i.e., the
drug-loaded CA-PLA-TPGS nanoparticles and Taxol®,
were injected intra-tumorally at a single dose of 10 mg
PTX/kg in PBS on days 0, 4, and 8. Physiological saline
served as control. Mice were sacrificed by decapitation 12
days after treatment. The terminal tumor weight (mg) was
determined and applied to evaluate the antitumor effects.
Statistical methods
All experiments were performed at least three times unless
otherwise mentioned. Student's t test statistical analysis
was carried out with SPSS 17.0 software, with P < 0.05
considered to indicate a significant difference.
Results and discussions
Characterization of CA-PLA-TPGS copolymers
In order to confirm the formation of the CA-PLA-TPGS
copolymer, 1H NMR spectrum is recorded and is shown
in Figure 1A. For the CA-functionalized star-shaped
polymer CA-PLA-TPGS, the typical signals from CAmoiety, TPGS moiety, and LA monomer repeating units
can be observed. 1H NMR (CDCl3): a (δ = 1.62 ppm, LA
repeating unit: -CHCH3), b (δ = 5.21 ppm, LA repeating
unit: -CHCH3), c (δ = 3.65 ppm, TPGS repeating unit:
-CH2CH2O-), d (δ = 0.50 to 2.40 ppm, CA moiety:
-CH2- and -CH-), e (δ = 4.38 ppm, terminal hydroxyl
group of CA-PLA: -CHOH). Figure 1B shows the FTIR
spectra of the CA-PLA-TPGS copolymer and TPGS.
The carbonyl band of TPGS appears at 1,730 cm−1. For
the CA-PLA-TPGS copolymer, the carbonyl band was
shifted to 1,755 cm−1. Overlapping of the CH stretching
band of PLA at 2,945 cm−1 and that of TPGS at 2,880 cm−1
was observed. The absorption band at 3,400 to 3,650 cm−1
is attributed to the terminal hydroxyl group, and that at
1,050 to 1,250 cm−1 is due to the C-O stretching. The
results confirmed that the CA-PLA-TPGS copolymer was
synthesized by ring-opening polymerization.
Nanoparticle fabrication
PTX-loaded CA-PLA-TPGS nanoparticles were produced
by a modified nanoprecipitation method, in which acetone
was chosen as an acceptable solvent. Nanoprecipitation
could provide a mild, facile, and low energy input method
for the fabrication of polymeric nanoparticles [31]. The
drug and polymer could be completely dissolved in
acetone to form a clear and homogenous solution.
After that, the acetone solution was injected into an
aqueous solution under stirring to precipitate the
water-insoluble PTX instantaneously. Meanwhile, a rapid
precipitation of the hydrophobic PLA segment of the
star-shaped copolymer occurs, resulting in spontan-
eous production of PTX-encapsulated CA-PLA-TPGS
nanoparticles [9]. A stable dispersion of PTX-loaded
nanoparticles was then produced after stirring to remove
organic solvent acetone. In the end, the nanoparticles
exhibit a core-shell configuration with hydrophobic PLA
as the core encapsulating water-insoluble PTX and the
TPGS segment as the hydrophilic stabilization shell [9].
Nanoparticle characterization
Size, surface morphology, zeta potential, and entrapment
efficiency
The particle size and size distribution of the PTX-loaded
nanoparticles were detected using dynamic light scattering
(DLS) equipment, and the data were displayed in Table 1.
Particle size and surface properties of the nanoparticles
play a crucial role in drug release kinetics, cellular uptake
behavior, as well as in vivo pharmacokinetics and tissue
distribution [32]. The average hydrodynamic size of the
PTX-loaded nanoparticles is approximately 110 ~ 140 nm
in diameter, which is in the excellent size range for accu-
mulating readily in the tumor vasculature due to en-
hanced permeation and retention effects [33]. The results
revealed that the size of the CA-PLA-TPGS nanoparticles
Figure 1 1H NMR and FTIR spectra. (A) Typical 1H NMR spectrum of the CA-PLA-TPGS copolymer. (B) FTIR spectra of the CA-PLA-TPGS
copolymer (black) and TPGS (blue).
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PLA-TPGS nanoparticles; this was probably due to
the star-shaped and constrained geometry architecture of
the copolymer. In the present study, both star-shaped
CA-PLA-TPGS nanoparticles and linear PLA-TPGS
nanoparticles showed a relatively narrow particle size
distribution (PDI < 0.20), which makes them particularly
suitable for use in drug delivery systems. The size distribu-
tion of the PTX-loaded CA-PLA-TPGS nanoparticles
obtained from DLS is displayed in Figure 2A.
In an attempt to observe the surface morphology of
the nanoparticles, the FESEM study was performed. It
can be seen from Figure 3 that all the nanoparticles have
a nearly spherical shape and the mean particle size is
about 120 nm, which is in agreement with the data from
the DLS experiment.
Zeta potential is an important predictor of dispersion
stability of nanoparticles. A high absolute value of the zeta
potential means high surface charge of the nanoparticles.
The zeta potential distribution of the PTX-loaded
star-shaped CA-PLA-TPGS nanoparticles is displayed
in Figure 2B. As displayed in Table 1, the zeta potential
of the PTX-loaded CA-PLA-TPGS nanoparticles and the
PLA-TPGS nanoparticles was determined to be −13.0
and −19.3 mV, respectively, which is slightly higher
than that of the PLGA nanoparticles of zeta potential
about −22.8 mV. The negative surface charge of theTable 1 Characterization of PTX-loaded nanoparticles
Polymer Size (nm) PDI ZP (mV) LC (%) EE (%)
PLGA 134.3 ± 4.8 0.267 −22.8 ± 0.2 8.01 76.39
PLA-TPGS 125.7 ± 3.5 0.195 −19.3 ± 0.4 8.64 84.33
CA-PLA-TPGS 112.9 ± 3.1 0.179 −13.0 ± 0.9 10.05 98.81
PDI, polydispersity index; ZP, zeta potential; LC, loading content; EE,
entrapment efficiency; n = 3.nanoparticles may be due to the presence of ionized
carboxyl groups of PLA and PGA segments [28].
It can also be found from Table 1 that the contents of
drug loading and entrapment efficiency of the CA-PLA-
TPGS nanoparticles were higher than those of the
PLA-TPGS nanoparticles and the PLGA nanoparticles,
indicating the higher binding affinity between the
star-shaped core region PLGA and hydrophobic PTX.
Moreover, the drug loading content of PTX in the
CA-PLA-TPGS nanoparticles could reach approximately
10.0% which is ideal for an efficient drug delivery vehicle.
After redispersion in PBS, the mean size and size distribu-
tion of the PTX-loaded nanoparticles were nearly not
changed during the 3 months of follow-up, suggesting that
the PTX-loaded nanoparticles had good stability and
redispersion ability.
Stability of PTX-loaded nanoparticles
In biomedical applications, nanoparticles have to be
hydrophilic and maintain a superior stability in bio-
logical media. Hydrophilic PEG has been the focus of
research as an effective coating material for hydrophobic
nanoparticles due to its ability to resist protein fouling
and provide steric hindrance preventing nanoparticles
from aggregation [34]. In this research, TPGS is a
water-soluble PEG derivative of the natural form of
D-α-tocopherol, which may play an important role in
ensuring nanoparticle stability. During the storage of
the nanoformulation, the absolute value of the zeta
potential usually becomes low and the nanoparticles
become aggregated, so the size distribution was uneven
and the nanoparticles are not so suitable for therapy as
the fresh nanoparticles. Thus, we measure the aver-
age size and size distribution and the zeta potential
of PTX-loaded CA-PLA-TPGS nanoparticles stored at
4°C at days 7, 14, 28, 42, 56, 70, and 90 after the
Figure 2 Size distribution and zeta potential distribution. (A) Size distribution of the star-shaped CA-PLA-TPGS nanoparticles detected by
DLS. (B) Zeta potential distribution of the star-shaped CA-PLA-TPGS nanoparticles.
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the size (Figure 4A) and zeta potential (Figure 4B)
were not obviously changed at 4°C after 3-month
storage, which means that PTX-loaded CA-PLA-TPGS
nanoparticles are very stable.Figure 3 FESEM image of the star-shaped CA-PLA-TPGS nanoparticlesIn vitro drug release assay
The in vitro drug release profiles of the PTX-loaded
nanoparticles in PBS (containing 0.1% w/v Tween 80,
pH 7.4) in the first 28 days are displayed in Figure 5.
Tween 80 was applied to improve the solubility of PTX.
Figure 4 In vitro stability of the PTX-loaded nanoparticles. (A) The size distribution of PTX-loaded PLGA, PLA-TPGS, and CA-PLA-TPGS NPs for
90-day storage at 4°C. (B) The zeta potential of PTX-loaded PLGA, PLA-TPGS, and CA-PLA-TPGS NPs for 90-day storage at 4°C.
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onto the tube wall [35]. The continuous release of drugs
from the polymeric nanoparticles could occur either by
diffusion of the drug from the polymer matrix or by the
erosion of the polymer, which are affected by constitu-
ents and architectures of the polymers, surface erosion
properties of the nanoparticles, and the physicochemical
properties of the drugs [36]. It can be seen from Figure 4
that the release profiles of the PTX-loaded nanoparticles
displayed typically biphasic release patterns. The initial
burst release in the first 5 days was due to the drug
poorly encapsulated in the polymeric core and just
located beneath the periphery of the nanoparticles, while
the subsequent sustained release was predominantly
attributed to the diffusion of the drug, which was wellFigure 5 In vitro release profiles of the PTX-loaded linear PLGA nanop
CA-PLA-TPGS nanoparticles.entrapped in the core of nanoparticles. The PTX release
from the PLGA nanoparticles, PLA-TPGS nanoparticles,
and CA-PLA-TPGS nanoparticles displayed an initial
burst of 33.35%, 39.85%, and 47.38% in the first 5 days,
respectively. After 28 days, the accumulative PTX release
of nanoparticles reached 45% ~ 65%. The accumula-
tive PTX release in the first 28 days was found in the
following order: CA-PLA-TPGS nanoparticles > PLA-TPGS
nanoparticles > PLGA nanoparticles. The CA-PLA-TPGS
nanoparticles displayed the fastest drug release, indi-
cating that the star-shaped CA-PLA-TPGS copolymer
was capable of displaying faster drug release than the
linear PLA-TPGS nanoparticles when the copolymers
had the same molecular weight. In comparison with
the linear PLGA nanoparticles, the faster drug releasearticles, linear PLA-TPGS nanoparticles, and star-shaped
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hydrophilicity of the TPGS shell, resulting in an easier
environment for release medium penetration into the
nanoparticle core to make the polymer matrix swell.
Similar results can be found in the literature [37,38].
Cellular uptake of fluorescent CA-PLA-TPGS nanoparticles
The therapeutic effects of the drug-loaded polymeric
nanoparticles were dependent on internalization and
sustained retention of the nanoparticles by the tumor
cells [39]. The in vitro studies were capable of providing
some circumstantial evidence to show the advantages of
the nanoparticle formulation compared with the free
drug. Coumarin-6 served as a fluorescent probe in an
attempt to represent the drug in the nanoparticles for
visualization and quantitative analysis of cellular uptake
of the nanoparticles [40]. Figure 6 shows the CLSM
images of MCF-7 cells after 24 h of incubation with cou-
marin 6-loaded CA-PLA-TPGS nanoparticle dispersion
in DMEM at the concentration of 250 μg/mL. The
images were acquired from (A) the enhanced green
fluorescent protein (EGFP) channel (green), (B) the
DAPI channel (blue), and (C) the overlay of the two
channels. It can be seen from this figure that the couma-
rin 6-loaded CA-PLA-TPGS nanoparticles (green) were
closely located around the nuclei (blue, stained by
DAPI), indicating that the fluorescent nanoparticles had
been internalized into the MCF-7 cells.
The cellular uptake efficiency of the coumarin 6-loaded
nanoparticles was also measured, and the data are displayed
in Figure 7. It can be seen from this picture that the cellular
uptake efficiency of all coumarin 6-loaded nanoparticles
decreased with the increase of the incubated nanoparticle
concentration from 100 to 500 μg/mL. The cellular uptake
efficiency of the CA-PLA-TPGS nanoparticles was
1.20-, 1.20-, and 1.14-fold higher than that of the
PLA-TPGS nanoparticles at the nanoparticle concentra-
tion of 100, 250, and 500 μg/mL, respectively. This may be
because of the smaller particle size and increased cellFigure 6 CLSM images of MCF-7 cells after 4 h of incubation with the
6-loaded nanoparticles were green, and the cells were stained by DAPI (blu
using the EGFP filter and DAPI filter: (A) EGFP channel, green; (B) DAPI chaadherence capacity of the CA-PLA-TPGS nanoparticles.
The results also showed that the cell uptake efficiency of
both the star-shaped CA-PLA-TPGS nanoparticles and the
linear PLA-TPGS nanoparticles was higher than that of the
linear PLGA nanoparticles. It has been reported in the lit-
erature that particle size plays a predominant role in the
cellular uptake of biodegradable polymeric nanoparticles
[41]. Thus, it can be believed that the CA-PLA-TPGS
nanoparticles with smaller particle size would have higher
cellular uptake efficiency. Similar results were also obtained
by other researchers [42].
In vitro cell viability of PTX-loaded nanoparticles
Human MCF-7 cell lines were applied to investigate the
cytotoxicity of PTX-loaded nanoparticles. The clinical PTX
formulation (Taxol®) was designed as the positive control.
The different groups of nanoparticles were sterilized using
gamma radiation. Figure 8 displays the in vitro cell viability
of PTX formulated in the linear PLA-TPGS nanoparticles,
star-shaped CA-PLA-TPGS nanoparticles, and Taxol® at
equivalent PTX concentrations of 0.25, 2.5, 10, and
25 μg/mL. A quantitative colorimetric assay of MTT
was used to determine the percentage of viable cells
[42]. It can be concluded from Figure 8 that (a) the cell
suppression of Taxol® and the drug-loaded polymeric
nanoparticles showed both dose- and time-dependent re-
sponses. The cell viability decreased steadily with increas-
ing drug dose and incubation time, especially for the
drug-loaded star-shaped CA-PLA-TPGS nanoparticles. (b)
Though no significant difference in cytotoxicity could
be observed among the three formulations after 24 h
of incubation, the PTX-loaded star-shaped CA-PLA-TPGS
nanoparticles did show much higher cytotoxicity efficacy
against MCF-7 cells than the linear PLA-TPGS nano-
particles and Taxol® after 48 and 72 h of incubation. Figure 8
also shows that the MCF-7 cell viability after 24 h of incu-
bation at 10 μg/mL of drug concentration was 68.35% for
Taxol®, 70.75% for the linear PLA-TPGS nanoparticles, and
69.22% for the star-shaped CA-PLA-TPGS nanoparticles.coumarin 6-loaded CA-PLA-TPGS nanoparticles. The coumarin
e). The cellular uptake was visualized by overlaying images obtained
nnel, blue; and (C) combined EGFP channel and DAPI channel.
Figure 7 Cellular uptake efficiency of the coumarin 6-loaded nanoparticles.
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MCF-7 cells demonstrated 17.04% and 20.12% higher cyto-
toxicity for the PTX-loaded star-shaped CA-PLA-TPGS
nanoparticles after 48 and 72 h of incubation at the drug
concentration of 10 μg/mL, respectively (P < 0.05, n = 6).
It can also be found that the PTX-loaded star-shaped
CA-PLA-TPGS nanoparticles showed increasingly higher
therapeutic efficacy for MCF-7 cells than the clinical Taxol®
formulation and the linear PLA-TPGS nanoparticles with
increasing incubation time. This could be due to the
higher cellular uptake and the faster drug release of the
PTX-loaded star-shaped CA-PLA-TPGS nanoparticles.
The best therapeutic activity in MCF-7 cells was found for
the PTX-loaded star-shaped CA-PLA-TPGS nanoparticles
at 25 μg/mL of equivalent drug concentration, which
could reach as low as 17.09% cell viability after 72 h of
incubation. This might be attributed to the enough PTX
released from the polymeric nanoparticles and the TPGSFigure 8 Cell viability of PTX-loaded nanoparticles compared with tha
concentration. (A) 24 h. (B) 48 h. (C) 72 h.component from degradation of the polymer matrix.
As we know, TPGS is also cytotoxic and may produce
synergistic anticancer effects with PTX [43-45].
The advantages in cancer cell inhibition of the CA-
PLA-TPGS nanoparticle formulation > PLA-TPGS nano-
particle formulation > commercial Taxol® formulation
could be quantitatively demonstrated in terms of their
IC50 values, which is defined as the drug inhibitory
concentration that is required to cause 50% tumor
cell mortality in a designated period. The IC50 values
of the three PTX formulations of Taxol®, the linear
PLA-TPGS nanoparticles, and the star-shaped CA-PLA-
TPGS nanoparticles on MCF-7 cells after 24, 48, and 72 h
of incubation are displayed in Table 2, which are calculated
from Figure 8. It can be seen from Table 2 that the IC50
value of the PTX-loaded CA-PLA-TPGS nanoparticles on
MCF-7 cells was 46.63 μg/mL, which was a degree higher
than that of Taxol® after 24 h of incubation. However, thet of Taxol® at equivalent PTX dose and nanoparticle
Table 2 IC50 values of PTX formulations of Taxol®, PLA-TPGS
nanoparticles, and CA-PLA-TPGS nanoparticles on MCF-7




Taxol® PLA-TPGS NPs CA-PLA-TPGS NPs
24 45.47 49.20 46.63
48 38.13 35.41 34.71
72 28.32 27.40 15.22
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http://www.nanoscalereslett.com/content/8/1/420IC50 value of Taxol® on MCF-7 cells decreased from 38.13
to 28.32 μg/mL, and that of the PTX-loaded star-shaped
CA-PLA-TPGS nanoparticles decreased from 34.71 to
15.22 μg/mL for after 48 and 72 h of incubation, re-
spectively. It can be concluded that the PTX-loaded
nanoparticles displayed significantly higher cytotoxicity to
MCF-7 cells due to the sustained drug release manner. In
short, the nanoparticles of the star-shaped copolymer
CA-PLA-TPGS were able to achieve better therapeutic
effects than those of the linear copolymer PLA-TPGS.
Animal studies
The advantages of PTX-loaded star-shaped CA-PLA-
TPGS nanoparticles in breast cancer therapy were further
confirmed in an animal model. In the present study, SCID
mice bearing xenografts of a human breast carcinoma cell
line were used to investigate the in vivo therapeutic effects
of the star-shaped CA-PLA-TPGS nanoparticle formula-
tion of PTX vs. Taxol®. The PTX-loaded CA-PLA-TPGS
nanoparticle formulation was injected into the tumor
every 4 days for three consecutive cycles. The tumor
volume of the mice was monitored every 2 days until theFigure 9 Tumor growth curve of the mice after injection of the PTX-lo12th day, which was performed in comparison with the
animal treated with Taxol®. Animals injected with vehicle
(physiological saline, 0.9% NaCl) served as control.
Figure 9 shows the tumor growth surveyed for 12 days in
the mice after the intra-tumoral injection of the PTX-
loaded CA-PLA-TPGS nanoparticles, Taxol®, and saline. It
can be seen from this figure that the tumor size of the con-
trol group showed a statistically significant increase during
the experimental period. However, the tumor growth of the
groups treated with Taxol® and the PTX-loaded star-shaped
CA-PLA-TPGS nanoparticles was inhibited significantly.
The tumor growth followed the order CA-PLA-TPGS
nanoparticle treatment < Taxol® < saline. In conclusion,
such nanoparticles of star-shaped cholic acid-core PLA-
TPGS block copolymer could be considered as a potentially
promising and effective strategy for breast cancer treatment.
Conclusions
A novel carrier system of star-shaped CA-PLA-TPGS
nanoparticles for sustained and controlled delivery of
paclitaxel for breast cancer treatment was developed in
this research, which was compared with drug-loaded lin-
ear PLGA nanoparticles and linear PLA-TPGS copoly-
mer nanoparticles. The three nanoparticle formulations
were fabricated by a modified nanoprecipitation proced-
ure. The particle size of the PTX-loaded star-shaped
CA-PLA-TPGS nanoparticles could be prepared favor-
ably approximately 120 nm in diameter. The star-shaped
CA-PLA-TPGS nanoparticles could achieve higher drug
loading content and entrapment efficiency, resulting in
faster drug release as well as higher cellular uptake and
cytotoxicity than the linear PLGA nanoparticles and theaded CA-PLA-TPGS nanoparticles, Taxol®, and saline (n = 5).
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http://www.nanoscalereslett.com/content/8/1/420linear PLA-TPGS nanoparticles. The drug-loaded
CA-PLA-TPGS nanoparticles were found to be stable,
showing no change in the particle size and surface
charge during 90-day storage of the aqueous solution.
The in vivo cell studies indicated that the PTX-loaded
star-shaped CA-PLA-TPGS nanoparticles were able to
show significantly superior antitumor activity than the lin-
ear PLA-TPGS nanoparticle formulation and the clinical
formulation Taxol®. In this research, the great advantages
of such star-shaped CA-PLA-TPGS nanoparticles for
paclitaxel formulation for breast cancer treatment
were reported, which can also be used to other drugs of
difficulty in formulation owing to high hydrophobicity.
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